You are here: Industry Insights > Asthma

News List

FDA approves Sanofi/Regeneron’s Dupixent in asthma pharmaphorum
December 21, 2018
The US regulator has approved Sanofi/Regeneron’s Dupixent (dupilumab) in a new asthma indication, a key step in the companies attempt to build a blockbuster franchise around the drug.
Sanofi inks research deal to create digital asthma lab fiercepharma
December 06, 2018
Sanofi plans to take asthma research where it has not gone before.
Sanofi merges biology and tech with research deal for digital asthma lab fiercepharma
December 06, 2018
Sanofi plans to take asthma research where it has not gone before. A new partnership with Mount Sinai Health System and advanced analytics firm Sema4 will create a digital asthma
Vectura pulls the plug on experimental asthma therapy contractpharma
November 28, 2018
Vectura says it no longer plans to develop and partner experimental asthma therapy VR475, after it failed to hit Phase III targets.
US grants AZ’ Fasenra orphan drug status for rare autoimmune disease pharmatimes
November 27, 2018
US regulators have granted AstraZeneca’s Fasenra Orphan Drug Designation (ODD) for the treatment of Eosinophilic Granulomatosis with Polyangiitis (EGPA), a rare and potentially fatal autoimmune disease.
UK first EU nation to launch flutiform k-haler for asthma pharmatimes
November 27, 2018
Napp Pharmaceuticals says the UK is the first country in Europe to launch flutiform k-haler, a breath-actuate inhaler for adolescents and adults living with asthma.
flutiform Receives Positive Opinion in Europe americanpharmaceuticalreview
November 10, 2018
flutiform has been available in Europe for the treatment of asthma in adults and adolescents (≥12 years old) since 2012 and has a tolerability profile supported by extensive clinical evidence and real-world use for six years across Europe and Asia-Pacific
Long-term data backs safety and efficacy of GSK’s Nucala pharmatimes
November 05, 2018
GlaxoSmithKline has reported long-term safety data showing a sustained reduction in severe asthma attacks and improved asthma control ...
Sanofi's Dupixent set for $2.5B in peak asthma sales after scoring winning label fiercepharma
October 23, 2018
Even as its diabetes unit struggles, Sanofi has made strides on the market with Dupixent since launching last year in eczema.
FDA approves Regeneron, Sanofi's Dupixent for asthma treatment biospectrum
October 23, 2018
Regeneron and Sanofi recognize that DUPIXENT can only help those uncontrolled moderate-to-severe AD patients that were prescribed the medicine if they can both access the medicine and use it properly.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 14 15 Next page